Closer to 90-90-90. The cascade of care after 10 years of ART scale-up in rural Malawi: A population study

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Maman, David ^a   Chilima, Benson ^b   Masiku, Charles ^c   Ayouba, Ahidjo ^d   Masson, Sophie ^a   Szumilin, Elisabeth ^c   Peeters, Martine ^d   Ford, Nathan ^e   Heinzelmann, Annette ^c   Riche, Benjamin ^f,g,h   Etard, Jean François ^a,d  

^a EPICENTRE   (France)

^b MINISTRY OF HEALTH   (Malawi)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d UNIVERSITÉ DE MONTPELLIER   (France)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f HOSPICES CIVILS DE LYON   (France)

^g UNIVERSITÉ DE LYON   (France)

^h LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

Author keywords

HIV; Incidence; Prevalence; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ELISA KIT; HIV RAPID TEST; HOME CARE; HOUSEHOLD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALAWI; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RURAL AREA; SCALE UP; VIRUS LOAD; HIV INFECTIONS; MIDDLE AGED; PREVALENCE; RURAL POPULATION; VIROLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALAWI; MALE; MIDDLE AGED; PREVALENCE; RURAL POPULATION; VIRAL LOAD;

EID: 84960157836     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.20673     Document Type: Article

References (33)

1. UNAIDS. 90-90-90 an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014. p. 40.
2. UNAIDS. Report on the global AIDS epidemic. WHO Library Cataloguing-in-Publication Data. Geneva: UNAIDS; 2010.
3. Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013; 173: 1337-44.
4. Gardner EM, Young B. The HIV care cascade through time. Lancet Infect Dis. 2014; 14(1): 5-6.
5. Kilmarx PH, Mutasa-Apollo T. Patching a leaky pipe: The cascade of HIV care. Curr Opin HIV AIDS. 2013; 8(1): 59-64.
6. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: 2015.
7. National Statistical Office, ICF Macro. Malawi demographic and health survey 2010. Zomba, Malawi and Calverton (MD): NSO and ICF Macro; 2011.
8. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet. 2006; 367(9519): 1335-42.
9. McGuire M, Ben Farhat J, Pedrono G, Szumilin E, Heinzelmann A, Chinyumba YN, et al. Task-sharing of HIV care and ART initiation: Evaluation of a mixed-care non-physician provider model for ART delivery in rural Malawi. PLoS One. 2013; 8(9): E74090.
10. Vaessen M, Thiam M, Lê T. Household sample surveys in developing and transition countries. millenniumindicators.un.org. New York: United Nations; 2005.
11. Mishra V, Vaessen M, Boerma JT, Arnold F, Way A, Barrere B, et al. HIV testing in national population-based surveys: Experience from the Demographic and Health Surveys. Bull World Health Organ. 2006; 84: 537-45.
12. World Health Organization Working Group on HIV Incidence Assays. Framework for metrics to support effective treatment as prevention. Geneva, Switzerland: World Health Organization; 2012.
13. Ministry of Health. Clinical management of HIV in children and adults. Lilongwe, Malawi: Ministry of Health; 2011.
14. Kassanjee R, McWalter TA,Welte A. Defining optimality of a test for recent infection for HIV incidence surveillance. AIDS Res Hum Retroviruses. 2014; 30(1): 45-9.
15. Holtgrave D, Hall HI, Rhodes PH, Wolitski R. Updated annual HIV transmission rates in the United States, 1977-2006. J Acquir Immune Defic Syndr. 2009; 50(2): 236-8.
16. Justman J, Ellman T, Donnell D, Duong YT, Reed J, Bicego GT, et al. Population HIV viral load in Swaziland: Assessing ART program effectiveness and transmission potential. Conference on Retroviruses and Opportunistic Infections. Atlanta; 2013. Abstract 96.
17. Kranzer K, Lawn SD, Johnson LF, Bekker L-G,Wood R. Community viral load and CD4 count distribution among people living with HIV in a South African Township: Implications for treatment as prevention. J Acquir Immune Defic Syndr. 2013; 63(4): 498-505.
18. Nosyk B, Montaner JSG, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: A populationbased retrospective cohort study. Lancet Infect Dis. 2013; 3099(13): 1-10.
19. Miller WC, Powers KA, Smith MK, Cohen MS. Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis. 2013; 13(5): 459-64.
20. McGuire M, Pinoges L, Kanapathipillai R, Munyenyembe T, Huckabee M, Makombe S, et al. Treatment initiation, program attrition and patient treatment outcomes associated with scale-up and decentralization of HIV care in rural Malawi. PLoS One. 2012; 7(10): E38044.
21. Tassie J-M, Marquardt T, Damisoni H, Odhiambo OD, Mulemba M, Szumilin E, et al. Indirect markers to initiate highly active antiretroviral therapy in a rural African setting. AIDS. 2004; 18(8): 1226-8.
22. Tassie J-M, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource-poor settings: The experience of Médecins Sans Frontières. AIDS. 2003; 17(13): 1995-7.
23. Centers for Disease Control and Prevention (CDC). Impact of an innovative approach to prevent mother-To-child transmission of HIV+ Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep. 2013; 62(8): 148-51.
24. Reed JB, Justman J, Bicego G, Donnell D, Bock N, Ginindza H, et al. Estimating national HIV incidence from directly observed seroconversions in the Swaziland HIV Incidence Measurement Survey (SHIMS) longitudinal cohort. Washington, USA; 2012. Abstract FRLBX02.
25. Bicego GT, Nkambule R, Peterson I, Reed J, Donnell D, Ginindza H, et al. Recent patterns in population-based HIV prevalence in Swaziland. PLoS One. 2013; 8(10): E77101.
26. Kimanga DO, Ogola S, Umuro M, Ng'ang'a A, Kimondo L, Murithi P, et al. Prevalence and incidence of HIV infection, trends, and risk factors among persons aged 15-64 years in Kenya: Results from a nationally representative study. J Acquir Immune Defic Syndr. 2014; 66: S13-26. doi: Http://dx.doi.org/10. 1097/QAI.0000000000000124
27. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds B200, B350, and B500 Cells/mm3: Assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011; 53: 817-25.
28. Peltzer K, Matseke G, Mzolo T, Majaja M. Determinants of knowledge of HIV status in South Africa: Results from a population-based HIV survey. BMC Public Health. 2009; 9: 174.
29. Mishra V, Barrere B, Hong R, Khan S. Evaluation of bias in HIV seroprevalence estimates from national household surveys. Sex Transm Infect. 2008; 84(Suppl 1): I63-70.
30. Calleja JMG, Marum LH, Cárcamo CP, Kaetano L, Muttunga J, Way A. Lessons learned in the conduct, validation, and interpretation of national population based HIV surveys. AIDS. 2005; 19(Suppl 2): S9-17.
31. Reniers G, Eaton J. Refusal bias in HIV prevalence estimates from nationally representative seroprevalence surveys. AIDS. 2009; 23(5): 621-9.
32. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendationsguided antiretroviral therapy initiation on HIV incidence: The ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: Study protocol for a cluster randomised controlled trial. Trials. 2013; 14: 230.
33. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment -A study protocol for a cluster randomised trial. Trials. 2014; 15(1): 57.